

Manufacturers of Allopathic & Herbal Formulations, I.V. infusions & Medical Disposables

Ref: Integrated Filing (Financial)/Q1/2025-26

August 2, 2025

The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 524075

The Manager
Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051.

Symbol: ALBERTDAVD

Dear Sir / Madam.

Sub: Integrated Filing (Financial) for the first quarter ended 30th June, 2025

As per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, we are submitting herewith the Integrated Filing (Financial) for the first quarter ended 30th June, 2025 as per the prescribed format.

A. FINANCIAL RESULTS

The Unaudited Financial Results of the Company together with the Limited Review Report issued by the Statutory Auditors of the Company for the first quarter ended on 30th June, 2025 as approved by the Board of Directors of the Company at its meeting held today i.e., 2nd August, 2025 are enclosed.

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable

C. OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Not Applicable

D. DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (applicable only for annual filing i.e., 4th quarter)

Not Applicable



Regd. Office: Block-D, 3rd Floor, Gillander House, 8, Netaji Subhas Road, Kolkata - 700 001, India

Phone: +91-33-2262-8436 / 8456 / 8492 / 8439

Email: albertdavid@adlindia.in, Website: www.albertdavidindia.com, CIN: L51109WB1938PLC009490

Factories: Kolkata, Ghaziabad • Sales Depot: Kolkata, Lucknow, Patna





Manufacturers of Allopathic & Herbal Formulations, I.V. infusions & Medical Disposables

The Board Meeting commenced at 12:00 P.M. (IST) and concluded at 16:40 P.M. (IST).

The aforesaid information is being made available on the website of the Company i.e. www.albertdavidindia.com.

This is for your information and records.

Thanking you, Yours faithfully, For **Albert David Limited**

Lalit Lohia Digitally signed by Lalit Lohia Date: 2025.08.02 18:07:53 +05'30'

(Lalit Lohia)

Company Secretary & Compliance Officer

Encl.: As above



Regd. Office: Block -D, 3rd Floor, Gillander House, 8, Netaji Subhas Road, Kolkata - 700 001, India

Phone: +91-33-2262-8436 / 8456 / 8492 / 8439

Email: albertdavid@adlindia.in, Website: www.albertdavidindia.com, CIN: L51109WB1938PLC009490

Factories: Kolkata, Ghaziabad • Sales Depot: Kolkata, Lucknow, Patna



F2/2, GILLANDER HOUSE 8, NETAJI SUBHAS ROAD KOLKATA-700 001

TEL: +91-33-2242 5858/4277
FAX: +91-33-2242 0650

E-mall : lbjha@lbjha.com Website : www.lbjha.com

Limited Review Report

To The Board of Directors Albert David Limited

- 1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **Albert David Limited** ("the Company"), for the guarter ended June 30, 2025.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For L.B/Jha & Co.,

(Registration Number: 301088E)

D.N. Roy) Partner

(Membership No. 300389)

UDIN: 25300389BMHWRP5828

Place: Kolkata Date: 02.08.2025





Regd. Office: 'D' Block, 3rd Floor, Gillander House, Netaji Subhas Road, Kolkata-700001

(Corporate Identity No. : L51109WB1938PLC009490) Tel: 033-2262-8436/8456/8492, 2230-2330



Email: albertdavid@adlindia.in, Website: www.albertdavidindia.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

SI.	Particulars	Quarter Ended			Year ended
No.		30.06.2025	31.03.2025	30.06,2024	31.03.2025
		(Unaudited)	(Audited)	(Audited)	(Audited)
	I				
1	Income	7.056.64	7,489,33	8,935,64	34,576,80
	(a) Revenue from operations	2,203.62	-511.44	2,306,23	2,958.07
	(b) Other Income	2,200.02	311.41	2,000,20	2,000.01
	Total Income	9,260.26	6,977.89	11,241.87	37,534.87
2	Expenses				
	a) Cost of materials consumed	1,324.80	2,089.51	1,549.57	7,015.05
	b) Purchases of stock-in-trade	991.22	1,855,06	1,292,40	6,046.24
	c) Changes in inventories of finished goods,	211.98	-1,012.04	188.05	-1,432,98
	work-in-progress and stock-in-trade				
	d) Employee Benefits expenses	2,843.02	2,268.18	2,836,57	10,902,46
	e) Finance Costs	55.48	13,15	9.32	41,04
	f) Depreciation and Amortization expenses	238.87	181.75	178,50	696,89
	g) Other expenses	2,751.06	2,763,15	2,981,24	11,743,40
	1				
	Total Expenses	8,416.43	8,158.76	9,035.65	35,012.10
3	Profit/(Loss) before Exceptional Items and Tax (1-2)	843.83	-1,180.87	2,206.22	2,522.77
4	Exceptional Items		* <u>52</u>	181	
5	Profit/(Loss) before tax (3-4)	843.83	-1,180.87	2,206.22	2,522.77
6	Tax Expenses		.=0.04	140.47	500.40
	(a) Current Tax	(6)	178.84	118,17	592.42
	(b) Deferred Tax	50.07	-326.92	203,61	210,27
7	Profit/(Loss) for the Period (5-6)	793.76	-1,032.79	1,884.44	1,720.08
8	Other Comprehensive Income				
	(a) (i) Items that will not be reclassified to profit or loss	-24.54	-161.53	27,14	-38,60
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.18	43,76	-6.83	-74,90
	(b) (i) Items that will be reclassified to profit or loss			•	₹.
	(ii) Income tax relating to items that will be reclassified to profit or loss			-	51
9	Total Comprehensive Income for the period (7 + 8)	775.40	-1,150.56	1,904.75	1,606.58
	1 ()				
10	Paid-Up Equity Share Capital (Face value of Rs.10/-)	570.72	570.72	570.72	570.72
		10.11.11			
11	Other Equity		<u>=</u> :	-	38,677.62
12	Earning Per Equity Share of Rs.10/- each (not annualised)				
	(a) Basic (Rs.)	13.91	-18.10	33.02	30.14
	(b) Diluted (Rs.)	13.91	<u>-</u> 18.10	33.02	30_14

Notes:

- 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 2nd August, 2025. The Limited Review for the quarter ended 30th June, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015.
- 2. The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter ended 30th June, 2025
- The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 "Operating Segments".
- 4. Figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the figures upto the end of third quarter
- 5. Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI.

Place : Kolkata

Date: 2nd August, 2025



For ALBERT DAVID LIM

(U. M. Kunte) Managing Director & CE (DIN: 03398438)

N. S. Road Kulkula 700001